Brief: Maia Biotechnology Reports Second Quarter 2023 Financial Results
08/08/2023 14:04
Aug 8 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY REPORTS SECOND QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES UPDATES FOR THIO-101 PHASE 2 TRIAL FOR NON-SMALL
CELL LUNG CANCER
* MAIA BIOTECHNOLOGY INC - CASH TOTALING APPROXIMATELY $9.1
MILLION AS OF JUNE 30, 2023
Source text for Eikon: ID:nBw1DGdFKa
Further company coverage: MAIA.A
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale